AOA's position against use of placebos for pain management in end-of-life care.
A number of organizations have advised against the use of placebo substitution, including the American Pain Society, Agency for Healthcare Policy and Research, World Health Organization, Healthcare Facilities Accreditation Program, Joint Commission on Accreditation of Healthcare Organizations, Education for Physicians on End-of-Life Care Project (cosponsored by the American Medical Association and The Robert Wood Johnson Foundation), American Nursing Association, and the American Society of Pain Management Nurses. This white paper describes the literature and rationale in support of the American Osteopathic Association's (AOA's) position on the controversial subject of the use of placebos for pain management in terminally ill patients.
D001291:Attitude of Health Personnel; D026690:Ethics, Clinical; D019983:Guideline Adherence; D006801:Humans; D009294:Narcotics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D009293:Opioid-Related Disorders / Q000209:etiology / Q000517:prevention & control; D010021:Osteopathic Medicine; D010146:Pain / Q000188:drug therapy*; D010166:Palliative Care / Q000941:ethics / Q000331:legislation & jurisprudence / Q000592:standards*; D028701:Patient Rights / Q000331:legislation & jurisprudence; D010919:Placebos / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D013727:Terminal Care / Q000331:legislation & jurisprudence / Q000379:methods / Q000592:standards*; D014481:United States
D009294:Narcotics; D010919:Placebos